[
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy Hand Over Fist in April",
    "summary": "This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.  Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical companies Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).  Amgen's involvement in the high-demand obesity drugs race has attracted attention recently, but the pharmaceutical sector star has been on the radar of clever investors for years.",
    "url": "https://finnhub.io/api/news?id=47fa695a11178c36c8983cee635d9ce915c658ed10229424a26a0498827c68e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743856200,
      "headline": "2 Dividend Stocks to Buy Hand Over Fist in April",
      "id": 133727291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.  Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical companies Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).  Amgen's involvement in the high-demand obesity drugs race has attracted attention recently, but the pharmaceutical sector star has been on the radar of clever investors for years.",
      "url": "https://finnhub.io/api/news?id=47fa695a11178c36c8983cee635d9ce915c658ed10229424a26a0498827c68e4"
    }
  }
]